MedTrace Logo

Safety and Efficacy of Rasagiline in Restless Legs Syndrome

NCT01192503 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2013-02-11

No results posted yet for this study

Summary

The purpose of this study is to find out if rasagiline improves RLS symptoms. We also want to make sure rasagiline is safe to give people with RLS.

Conditions

  • Restless Legs Syndrome

Interventions

DRUG

rasagiline

1mg (2 tablets of 0.5mg) at bedtime taken by mouth for 12 weeks

DRUG

placebo (sugar pill)

1mg (2 tablets of 0.5mg) taken at bedtime by mouth for 12 weeks

Sponsors & Collaborators

  • Teva Neuroscience, Inc.

    collaborator INDUSTRY

  • University of Virginia

    lead OTHER

Principal Investigators

  • Tiffini S Voss, MD · University of Virginia, Department of Neurology

  • Bernad Ravina, MD. MSCE · University of Rochester, Movement and Inherited Neurological Disorders Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-06-30
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01192503 on ClinicalTrials.gov